Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
复制标题
DOI：
10.1038/s41586-021-04085-y
复制
发表时间：
2021-12
期刊：
影响因子：
64.8
通讯作者：
中科院分区：
文献类型：
--
作者：
主要中和抗体结合位点发生突变的 SARS-CoV-2 变体的出现可能会影响感染或疫苗接种诱导的体液免疫。我们分析了接受 SARS-CoV-2 mRNA 疫苗的先前感染（康复）或未感染（未感染）个体中抗 SARS-CoV-2 抗体和 T 细胞反应的发展。虽然先前感染的个体在接种疫苗后比未感染的个体维持更高的抗体滴度，但后者在第二剂疫苗接种后达到了对祖先毒株的中和反应水平。在体外刺激刺突或核衣壳肽时测量的 T 细胞活化标记物在疫苗接种后显示逐渐增加。使用 16 个本地流行的不同 SARS-CoV-2 变体的真实分离株对血浆中和进行综合分析，揭示了与刺突基因特定突变相关的中和能力的一系列降低：E484K 和 N501Y/T 谱系（例如 B.1.351 和 P.1）下降幅度最大，其次是 L452R 谱系（例如 B.1.617.2）。虽然两组都保留了针对所有变体的中和能力，但与也接受了两剂疫苗的未感染个体的血浆相比，先前感染的疫苗个体的血浆表现出总体更好的中和能力，这表明疫苗加强剂是减轻新出现的变体对抗体中和活性影响的相关未来策略。
The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-binding sites can affect humoral immunity induced by infection or vaccination. We analysed the development of anti-SARS-CoV-2 antibody and T cell responses in previously infected (recovered) or uninfected (naive) individuals that received mRNA vaccines to SARS-CoV-2. While previously infected individuals sustained higher antibody titers than uninfected individuals post-vaccination, the latter reached comparable levels of neutralization responses to the ancestral strain after the second vaccine dose. T cell activation markers measured upon spike or nucleocapsid peptide in vitro stimulation showed a progressive increase after vaccination. Comprehensive analysis of plasma neutralization using 16 authentic isolates of distinct locally circulating SARS-CoV-2 variants revealed a range of reduction in the neutralization capacity associated with specific mutations in the spike gene: lineages with E484K and N501Y/T (e.g., B.1.351 and P.1) had the greatest reduction, followed by lineages with L452R (e.g., B.1.617.2). While both groups retained neutralization capacity against all variants, plasma from previously infected vaccinated individuals displayed overall better neutralization capacity when compared to plasma from uninfected individuals that also received two vaccine doses, pointing to vaccine boosters as a relevant future strategy to alleviate the impact of emerging variants on antibody neutralizing activity.
登录
查看更多内容
影响因子：
82.9
作者：
Lucas C;Klein J;Sundaram ME;Liu F;Wong P;Silva J;Mao T;Oh JE;Mohanty S;Huang J;Tokuyama M;Lu P;Venkataraman A;Park A;Israelow B;Vogels CBF;Muenker MC;Chang CH;Casanovas-Massana A;Moore AJ;Zell J;Fournier JB;Yale IMPACT Research Team;Wyllie AL;Campbell M;Lee AI;Chun HJ;Grubaugh ND;Schulz WL;Farhadian S;Dela Cruz C;Ring AM;Shaw AC;Wisnewski AV;Yildirim I;Ko AI;Omer SB;Iwasaki A
通讯作者：
Iwasaki A
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
DOI：
10.1016/s0140-6736(21)00183-5
发表时间：
2021-02-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者：
Faria NR
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F